PhD student University of Strathclyde Glasgow, Scotland, United Kingdom
Introduction: Toll-like receptor 4 (TLR4) plays a key component of the innate immune system that recognises lipopolysaccharides (LPS) from gram-negative bacteria and initiates downstream inflammatory signalling pathways (1). Synthetic analogues of the LPS activating moiety, (like monophosphoryl lipid A) have been developed and added as adjuvants into liposomes to enhance vaccine efficacy (2). In this study, a simplified analogue, FP-20, is incorporated into lipid nanoparticle (LNP) formulations to assess its impact on the physicochemical properties, and their in vitro and in vivo performance.
Learning Objectives:
Incorporate FP-20 in LNPs and record any change on their physicochemical properties, compared to a control
Assess potential in vitro differences in expression, after cell transfection with the adjuvant-incorporated LNPs
Evaluate if different FP-20 concentrations have an effect on the immunological response in vivo
